Meeting
2018 ASCO Annual Meeting
Which is better in CD19 CAR-T treatment of r/r B-ALL, CD28 or 4-1BB? A parallel trial under the same manufacturing process.
Authors
Peihua Lu
Hebei Yanda Lu Daopei Hospital, Langfang, China
Peihua Lu , Xin-an Lu , Xian Zhang , Min Xiong , Jianping Zhang , Xiaosu Zhou , Feifei Qi , Junfang Yang , Ting He
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Cellular Immunotherapy
Clinical Trial Registration Number
NCT03173417
Citation
J Clin Oncol 36, 2018 (suppl; abstr 3041)
DOI
10.1200/JCO.2018.36.15_suppl.3041
Abstract #
3041
Poster Bd #
255
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Outcomes among adult recipients of CD19 CAR T-cell therapy for Burkitt lymphoma.
First Author: Laura S. Samples
Poster
2020 ASCO Virtual Scientific Program
Real-world outcomes of elderly patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with chimeric antigen receptor T-cell (CAR-T) therapy.
First Author: Lindsey Fitzgerald
Poster
2020 ASCO Virtual Scientific Program
Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1.
First Author: Frederick Lundry Locke
Poster
2017 ASCO Annual Meeting
Efficacy of anti-CD19 chimeric antigen receptor modified T(CAR-T) cell therapy in Chinese patients with relapsed/refractory acute lymphocytic leukemia in a multicenter trial.
First Author: Lei Xiao